Vertex Pharmaceuticals
Organization
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotechnology firms to utilize an explicit strategy of rational drug design rather than combinatorial chemistry. The company focuses on developing and commercializing therapies for treating serious diseases, notably cystic fibrosis.
What experts have said about Vertex Pharmaceuticals
5 statements · 2 positive · 3 neutral
Vertex agreed to acquire Crinetics for $10 billion in cash.
“Vertex has agreed to buy Crenex for $10 billion in cash.”
Open the episode · Micron and Sandisk Drop; SpaceX Rating; Crinetics SoarsListen at 3:54
The Crinetics acquisition will give Vertex entry into endocrinology.
“This will give Vertex an entry into the endocrinology market.”
Open the episode · Micron and Sandisk Drop; SpaceX Rating; Crinetics SoarsListen at 4:09
Vertex Pharmaceuticals agreed to acquire Kinetics Pharma for $85 per share.
“Vertex Pharmaceuticals agreeing to acquire kinetics Pharma for 85 bucks a share.”
Open the episode · Crinetics Gains on Vertex Deal, Solstice Acquire Element, Terawulf JumpsListen at 1:07
The Vertex-Kinetics deal has approximately $10 billion equity value, or $8.8 billion net of cash.
“the driver for that total equity value, about $10 billion, 8.8 billion net of estimated cash.”
Open the episode · Crinetics Gains on Vertex Deal, Solstice Acquire Element, Terawulf JumpsListen at 1:25
Vertex had a $134 billion market capitalization before the deal.
“$134 billion market cap prior to this deal.”
Open the episode · Crinetics Gains on Vertex Deal, Solstice Acquire Element, Terawulf JumpsListen at 1:48
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
2 episodes featuring Vertex Pharmaceuticals
Stock Movers
Samsung fallout rattles memory stocks as SpaceX joins Nasdaq 100
The episode connects one semiconductor giant’s earnings with investor reactions across memory chips, aerospace, payments, and pharmaceuticals.
Jul 7, 2026 · 6 min
Stock Movers
Big deals test biotech, chemicals and AI infrastructure
The episode connects two large acquisitions with TeraWulf’s risky shift from Bitcoin mining to AI data centers.
Jul 6, 2026 · 7 min